Tianyin Pharmaceutical (OTCMKTS: TPIY) is a China-based specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of anti-infective and respiratory treatment products. Established in the late 1990s and headquartered in Chongqing, the company has built a reputation for its focus on high-quality pharmaceutical formulations aimed at treating bacterial and viral infections, as well as respiratory ailments. Over the years, Tianyin has expanded its product portfolio to include both finished dosage forms and active pharmaceutical ingredients (APIs).
The company’s core offerings span a diverse range of dosage formats, such as oral capsules, tablets, intravenous infusions and freeze-dried injectables. Among its key products are broad-spectrum antibiotics, anti-fungal agents, antiviral compounds and respiratory therapies designed to address conditions like pneumonia, bronchitis and viral upper respiratory infections. Tianyin’s manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards, and the company has pursued various quality certifications to ensure product safety, efficacy and compliance with international norms.
Tianyin Pharmaceutical serves a broad customer base across mainland China and selectively exports to markets in Southeast Asia, Africa and Latin America. Its commercial footprint includes collaborations with local distributors and regional healthcare institutions, enabling the company to reach both urban hospitals and rural clinics. Tianyin continues to invest in expanding its sales network and exploring partnerships that support its ambition to become a globally recognized supplier of anti-infective therapies.
Leadership at Tianyin Pharmaceutical combines experience in pharmaceutical science and international business. The company’s founder and chairman, Dr. Zhixiong Zhou, brings decades of expertise in drug development and manufacturing strategy. Under his guidance, Tianyin has strengthened its research capabilities through collaborations with academic institutions and leveraged its technical know-how to optimize production processes. The management team remains committed to R&D innovation, regulatory compliance and sustainable growth as Tianyin advances its position within the global pharmaceutical industry.
AI Generated. May Contain Errors.
Free TPIY Stock Alerts